241 related articles for article (PubMed ID: 36189597)
1. Photobiomodulation for Hypertension and Alzheimer's Disease.
Valverde A; Mitrofanis J
J Alzheimers Dis; 2022; 90(3):1045-1055. PubMed ID: 36189597
[TBL] [Abstract][Full Text] [Related]
2. Recent Mechanisms of Neurodegeneration and Photobiomodulation in the Context of Alzheimer's Disease.
Su M; Nizamutdinov D; Liu H; Huang JH
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298224
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Neurodegeneration: Integrating Photobiomodulation and Neurofeedback in Alzheimer's Dementia and Parkinson's: A Review.
Berman MH; Nichols TW
Photobiomodul Photomed Laser Surg; 2019 Oct; 37(10):623-634. PubMed ID: 31647776
[No Abstract] [Full Text] [Related]
4. The neuropathological diagnosis of Alzheimer's disease.
DeTure MA; Dickson DW
Mol Neurodegener; 2019 Aug; 14(1):32. PubMed ID: 31375134
[TBL] [Abstract][Full Text] [Related]
5. Pathophysiological Links Among Hypertension and Alzheimer's Disease.
Carnevale D; Perrotta M; Lembo G; Trimarco B
High Blood Press Cardiovasc Prev; 2016 Mar; 23(1):3-7. PubMed ID: 26054481
[TBL] [Abstract][Full Text] [Related]
6. Transplantation of bone marrow mesenchymal stem cells improves cognitive deficits and alleviates neuropathology in animal models of Alzheimer's disease: a meta-analytic review on potential mechanisms.
Qin C; Lu Y; Wang K; Bai L; Shi G; Huang Y; Li Y
Transl Neurodegener; 2020 May; 9(1):20. PubMed ID: 32460886
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of the effect of photobiomodulation on the neuroinflammatory response in animal models of neurodegenerative diseases.
Xie K; El Khoury H; Mitrofanis J; Austin PJ
Rev Neurosci; 2023 Jun; 34(4):459-481. PubMed ID: 36302150
[TBL] [Abstract][Full Text] [Related]
8. Cerebrovascular damage after midlife transient hypertension in non-transgenic and Alzheimer's disease rats.
Lai AY; Joo IL; Trivedi AU; Dorr A; Hill ME; Stefanovic B; McLaurin J
Brain Res; 2021 May; 1758():147369. PubMed ID: 33582120
[TBL] [Abstract][Full Text] [Related]
9. Photobiomodulation Using a Low-Level Light-Emitting Diode Improves Cognitive Dysfunction in the 5XFAD Mouse Model of Alzheimer's Disease.
Cho GM; Lee SY; Park JH; Kim MJ; Park KJ; Choi BT; Shin YI; Kim NG; Shin HK
J Gerontol A Biol Sci Med Sci; 2020 Mar; 75(4):631-639. PubMed ID: 30346494
[TBL] [Abstract][Full Text] [Related]
10. Photobiomodulation suppresses JNK3 by activation of ERK/MKP7 to attenuate AMPA receptor endocytosis in Alzheimer's disease.
Shen Q; Liu L; Gu X; Xing D
Aging Cell; 2021 Jan; 20(1):e13289. PubMed ID: 33336891
[TBL] [Abstract][Full Text] [Related]
11. Mid infrared light treatment attenuates cognitive decline and alters the gut microbiota community in APP/PS1 mouse model.
Wang M; Cao J; Amakye WK; Gong C; Li Q; Ren J
Biochem Biophys Res Commun; 2020 Feb; 523(1):60-65. PubMed ID: 31831179
[TBL] [Abstract][Full Text] [Related]
12. Translational research on reserve against neurodegenerative disease: consensus report of the International Conference on Cognitive Reserve in the Dementias and the Alzheimer's Association Reserve, Resilience and Protective Factors Professional Interest Area working groups.
Perneczky R; Kempermann G; Korczyn AD; Matthews FE; Ikram MA; Scarmeas N; Chetelat G; Stern Y; Ewers M
BMC Med; 2019 Feb; 17(1):47. PubMed ID: 30808345
[TBL] [Abstract][Full Text] [Related]
13. The behavioral, pathological and therapeutic features of the senescence-accelerated mouse prone 8 strain as an Alzheimer's disease animal model.
Cheng XR; Zhou WX; Zhang YX
Ageing Res Rev; 2014 Jan; 13():13-37. PubMed ID: 24269312
[TBL] [Abstract][Full Text] [Related]
14. Near-infrared light reduces β-amyloid-stimulated microglial toxicity and enhances survival of neurons: mechanisms of light therapy for Alzheimer's disease.
Stepanov YV; Golovynska I; Zhang R; Golovynskyi S; Stepanova LI; Gorbach O; Dovbynchuk T; Garmanchuk LV; Ohulchanskyy TY; Qu J
Alzheimers Res Ther; 2022 Jun; 14(1):84. PubMed ID: 35717405
[TBL] [Abstract][Full Text] [Related]
15. Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.
Vesey R; Birrell JM; Bolton C; Chipperfield RS; Blackwell AD; Dening TR; Sahakian BJ
CNS Drugs; 2002; 16(7):485-500. PubMed ID: 12056923
[TBL] [Abstract][Full Text] [Related]
16. Photobiomodulation for Alzheimer's Disease: Translating Basic Research to Clinical Application.
Enengl J; Hamblin MR; Dungel P
J Alzheimers Dis; 2020; 75(4):1073-1082. PubMed ID: 32390621
[TBL] [Abstract][Full Text] [Related]
17. Evidence to Consider Angiotensin II Receptor Blockers for the Treatment of Early Alzheimer's Disease.
Saavedra JM
Cell Mol Neurobiol; 2016 Mar; 36(2):259-79. PubMed ID: 26993513
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with five vascular risk factors causes cerebral amyloid angiopathy but no Alzheimer pathology in C57BL6 mice.
Foidl BM; Humpel C
Brain Behav Immun; 2019 May; 78():52-64. PubMed ID: 30664922
[TBL] [Abstract][Full Text] [Related]
19. Fatty acids, lipid metabolism and Alzheimer pathology.
Hooijmans CR; Kiliaan AJ
Eur J Pharmacol; 2008 May; 585(1):176-96. PubMed ID: 18378224
[TBL] [Abstract][Full Text] [Related]
20. Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the National Alzheimer's Coordinating Centre.
Toledo JB; Arnold SE; Raible K; Brettschneider J; Xie SX; Grossman M; Monsell SE; Kukull WA; Trojanowski JQ
Brain; 2013 Sep; 136(Pt 9):2697-706. PubMed ID: 23842566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
